azilsartan

Known as: 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid 
 

Topic mentions per year

Topic mentions per year

2008-2017
0102020082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The angiotensin II type 1 (AT1) receptor blocker (ARB) candesartan strongly reduces blood pressure (BP) in patients with… (More)
  • figure 2
Is this relevant?
2012
2012
BACKGROUND Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in… (More)
Is this relevant?
2012
2012
Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2011
2011
The angiotensin II (AII) antagonistic action of azilsartan (AZL) [2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. To compare this ARB… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2011
2011
BACKGROUND Azilsartan medoxomil is a newly approved angiotensin receptor blocker (ARB) reported to lower 24-h blood pressure more… (More)
Is this relevant?
2011
2011
AIM Hypertension often coexists with insulin resistance. However, most metabolic effects of the antihypertensive agents have been… (More)
Is this relevant?
2011
2011
Azilsartan medoxomil (AZL-M) is a unique angiotensin II receptor blocker (ARB) under development for the treatment of… (More)
  • table I
  • figure 3
  • figure 1
  • figure 2
  • table II
Is this relevant?
2011
2011
The pharmacological profile of a novel angiotensin II type 1 receptor blocker, azilsartan medoxomil, was compared with that of… (More)
Is this relevant?
2011
2011
Increased expression of plasminogen activator inhibitor type-I (PAI-1) in vessel walls seems to accelerate atherosclerosis… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?